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Abstract 31 
Fibroblast growth factor 21 (FGF21), follistatin and leukocyte cell-derived chemotaxin 2 32 
(LECT2) are novel hepatokines which are modulated by metabolic stresses. This study 33 
investigated whether exercise intensity modulates the hepatokine response to acute exercise. 34 
Ten young, healthy men undertook three 8-h experimental trials: moderate-intensity exercise 35 
(MOD; 55% V̇O2 peak), high-intensity exercise (HIGH; 75% V̇O2 peak) and control (CON; 36 
rest), in a randomised, counterbalanced order. Exercise trials commenced with a treadmill run 37 
of varied duration to match gross exercise energy expenditure between trials (MOD vs HIGH; 38 
2475 ± 70 vs 2488 ± 58 kJ). Circulating FGF21, follistatin, LECT2, glucagon, insulin, glucose 39 
and non-esterified fatty acids (NEFA) were measured before exercise and at 0, 1, 2, 4 and 7 h 40 
post-exercise.  41 
Plasma FGF21 concentrations were increased up to 4 h post-exercise compared to CON (P ≤ 42 
0.022) with greater increases observed at 1, 2 and 4 h post-exercise during HIGH vs MOD (P 43 
≤ 0.025). Irrespective of intensity (P ≥ 0.606), plasma follistatin concentrations were elevated 44 
at 4 and 7 h post-exercise (P ≤ 0.053). Plasma LECT2 concentrations were increased 45 
immediately post-exercise (P ≤ 0.046) but were not significant after correcting for plasma 46 
volume shifts. Plasma glucagon (1 h; P = 0.032) and NEFA (4 and 7 h; P ≤ 0.029) responses 47 
to exercise were accentuated in HIGH vs MOD. 48 
These findings demonstrate that acute exercise augments circulating FGF21 and follistatin. 49 
Exercise-induced changes in FGF21 are intensity-dependent and may support the greater 50 
metabolic benefit of high-intensity exercise.  51 
Key words: exercise, physical activity, hepatokines, liver, FGF21, follistatin, LECT2, insulin 52 
resistance   53 
4 
 
 
Introduction 54 
The liver plays an integral role in the regulation of metabolic homeostasis through inter-organ 55 
crosstalk with other metabolically active tissues (Iroz et al. 2015, Meex and Watt 2017). In 56 
recent years, several exclusively or predominantly liver-secreted proteins, termed hepatokines, 57 
have been identified as molecules possessing the capacity to exert potent metabolic effects, 58 
both locally and distally (Meex et al. 2015). These include fibroblast growth factor 21 (FGF21), 59 
shown to modulate glucose and lipid metabolism (Kharitonenkov et al. 2005, Potthoff et al. 60 
2009, Xu et al. 2009, BonDurant and Potthoff 2018); follistatin, demonstrated to regulate 61 
muscle growth (Amthor et al. 2004, Yaden et al. 2014) and  influence pancreatic beta cell 62 
function and survival (Zhao et al. 2015, Hansen et al. 2016a); and leukocyte cell-derived 63 
chemotaxin 2 (LECT2), which can promote both skeletal muscle and adipose tissue insulin 64 
resistance (Lan et al. 2014, Jung et al. 2018).  65 
Chronic positive energy balance (Toye et al. 2007, Kirpich et al. 2011), hepatic steatosis (Meex 66 
et al. 2015) and obesity-associated metabolic disease, modulate hepatic protein synthesis and 67 
hepatokine secretion (Fu et al. 2012; Meex et al. 2015). Recent research suggests that 68 
hepatokines may also be sensitive to acute perturbations in energy and substrate metabolism 69 
through coordinating metabolic responses between the liver and extra-hepatic tissues (Xu et al. 70 
2009, Lan et al. 2014, Hansen and Plomgaard 2016). For example, hepatokines are implicated 71 
in the coordination of metabolic responses to both fasting and feeding (Lan et al. 2014, Markan 72 
et al. 2014). Furthermore, hepatokines may participate in metabolic responses to exercise; 73 
potentially contributing to the acute metabolic benefit associated with physical exertion such 74 
as improved whole-body substrate metabolism and insulin sensitivity (Kim et al. 2013, Hansen 75 
et al. 2015, Weigert et al. 2018). 76 
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To date, a handful of studies have examined the acute effects of exercise on circulating 77 
hepatokines. This research has shown that exercise increases circulating levels of FGF21 and 78 
follistatin (Hansen et al. 2011, Kim et al. 2013, Hansen et al. 2015, Hansen et al. 2016a, Hansen 79 
et al. 2016b, Sargeant et al. 2018), whilst circulating LECT2 is suppressed after exercise in 80 
mice (Lan et al. 2014) but is unaffected in humans (Sargeant et al. 2018). Exercise intensity is 81 
a key variable which mediates the metabolic benefit of acute exercise, with protocols of higher 82 
intensity typically providing the greatest therapeutic effects (Wahren et al. 1978, Wen et al. 83 
2011). Given that FGF21, follistatin and LECT2 responses to exercise are mediated via 84 
metabolic factors sensitive to exercise intensity (for example, glucagon, insulin and non-85 
esterified fatty acids) (Hansen et al. 2015, Hansen et al. 2016a), it is possible that exercise 86 
intensity may also modulate circulating hepatokines.  87 
One previous study explored this hypothesis, demonstrating that circulating FGF21 was higher 88 
in healthy men, one hour after 30 minutes of treadmill running at 80% vs 50% of maximum 89 
oxygen uptake (Kim et al. 2013). This study was, however, limited by the fact that the exercise 90 
protocols were not matched for energy expenditure and no control trial was included. 91 
Consequently, further research is required to explore the impact of exercise intensity on 92 
circulating hepatokines by matching exercise-related energy expenditure between exercise 93 
protocols of different intensities; and to compare responses against a non-exercise control trial.   94 
Therefore, the present study investigated the effect of exercise intensity, using two energy-95 
matched exercise trials, on circulating concentrations of FGF21, follistatin and LECT2 in 96 
healthy men. Based on previous findings, it was hypothesised that both exercise intensities 97 
would lead to transient increases in circulating FGF21 and follistatin, whilst circulating LECT2 98 
levels would be reduced following exercise. Furthermore, these responses would be more 99 
pronounced after the performance of high- vs moderate-intensity exercise.  100 
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Materials and methods 101 
Participants 102 
Following approval from the Institutional Ethical Advisory Committee (ref: R16-P067), 10 103 
healthy men participated in the study. Participant characteristics are presented in Table 1. All 104 
participants were non-smokers, metabolically healthy, weight stable for three months prior to 105 
participation (< 2 kg body mass change) and were not currently taking any medications. Written 106 
informed consent was provided by each participant before data collection commenced. 107 
 108 
Insert table 1 109 
 110 
Participant pre-assessment 111 
Participants attended an initial pre-assessment session in which they completed a health screen 112 
questionnaire, the Physical Activity Readiness Questionnaire (PAR-Q+; Bredin et al. 2013) 113 
and food preference questionnaire, before undergoing anthropometric measurements. Height 114 
and body mass were measured using a wireless measuring station (Seca 285, Seca Ltd, 115 
Germany) and body mass index (BMI) was subsequently calculated. Waist circumference was 116 
measured at the smallest circumference between the xiphoid process and the iliac crest, whilst 117 
body composition was determined using bio-electrical impedance analysis (BC-418, TANITA, 118 
Europe BC, Amsterdam, the Netherlands).  119 
Participants then undertook a submaximal incremental exercise test on a motorised treadmill 120 
(Technogym Excite Med, Cesena, Italy), consisting of four, 4-min stages at progressively faster 121 
speeds, to determine the relationship between treadmill speed and oxygen consumption (V̇O2) 122 
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for each participant. The first stage commenced at a speed between 7-8 km∙h-1, with each 123 
subsequent stage increasing by 1-2 km∙h-1, according to participant fitness. Expired air was 124 
sampled continuously using breath-by-breath indirect calorimetry (Cortex Metalyzer 3B, 125 
Leipzig, Germany) to quantify V̇O2 and carbon dioxide production (V̇CO2). Heart rate was 126 
recorded continuously using short-range telemetry (Polar T31; Polar Electro, Kempele, 127 
Finland), whilst rating of perceived exertion (RPE; Borg. 1973) was assessed in the last 30 s 128 
of each stage.  129 
After a standardised rest period of 10 min, participants then completed an incremental maximal 130 
exercise test to determine peak oxygen uptake (V̇O2 peak). The test commenced at a gradient 131 
of 0% and increased by 1% every minute until volitional exhaustion. The maximal exercise 132 
test was designed to bring the participants to exhaustion within approximately 8-12 min and 133 
the treadmill speed was determined by the individual performance of each participant in the 134 
submaximal exercise test. The breath-by-breath data were analysed using a 30 s average 135 
(Robergs et al. 2010) to identify the participants’ V̇O2 peak.  136 
Experimental design 137 
Participants completed three main experimental trials: a moderate-intensity (MOD) trial, a 138 
high-intensity (HIGH) trial and a control (CON) trial. The main trials were carried out in a 139 
randomised, counterbalanced order, with at least five days separating each trial. In the 24 h 140 
prior to each main trial, participants were asked to standardise their food intake using a weighed 141 
food record and to abstain from exercise, caffeine and alcohol. Each main trial lasted 8 h 142 
(08:00-16:00) as shown schematically in Figure 1. 143 
 144 
Insert figure 1 145 
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  146 
Experimental protocol 147 
On the day of the main trials, participants arrived at the laboratory at 08:00 following an 148 
overnight fast of at least 10 h. During MOD and HIGH trials, participants performed a 149 
continuous treadmill run at moderate-intensity (55% V̇O2 peak) and high-intensity (75% V̇O2 150 
peak), respectively, resting thereafter. Participants rested throughout the CON trial. Both 151 
exercise protocols were designed to elicit a gross energy expenditure of 2510 kJ (600 kcal); 152 
meaning the exercise duration differed between MOD and HIGH. The treadmill speed required 153 
to elicit the target intensities was predicted via bivariate linear regression using participants’ 154 
V̇O2 peak and V̇O2-running speed relationship determined in the pre-assessment session. The 155 
rate of energy expenditure for each trial was then calculated using equations by Frayn (1983) 156 
and the exercise duration required to induce a gross energy expenditure of 2510 kJ was 157 
subsequently estimated. Expired air was sampled continuously during exercise to determine 158 
the actual gross energy expenditure and percentage substrate oxidation of the exercise period. 159 
The speed of the treadmill was adjusted, if necessary, to maintain the target V̇O2. Heart rate 160 
was monitored continuously throughout; whilst RPE was recorded every 10 min. Exercise 161 
commenced between 08:00 and 09:00 in a staggered fashion so that exercise finished at 09:00.  162 
A standardised breakfast (jam sandwich with butter, strawberry breakfast bar, banana and 163 
chocolate milkshake) was provided to the participants at 2 h post-exercise (11:00), containing 164 
an energy content equal to 35% of the participants’ estimated daily energy requirement and a 165 
macronutrient content of 69% carbohydrate, 14% protein and 17% fat. Individuals’ daily 166 
energy requirements were calculated from their estimated basal metabolic rate (BMR), which 167 
was multiplied by a physical activity correction factor of 1.4 (Mifflin et al. 1990) to reflect the 168 
sedentary nature of prolonged sitting in the laboratory during the main trials. A standardised 169 
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lunch (cheese sandwich with butter, salted crisps, mini chocolate roll and apple) was then 170 
provided at 6 h post-exercise (15:00), also containing 35% of the participants’ estimated daily 171 
energy requirement (42% carbohydrate, 13% protein and 45% fat).  172 
Blood sampling 173 
Venepuncture blood samples were taken from an antecubital vein upon arrival (baseline; 08:00) 174 
and immediately after exercise (0 h; 09:00). At approximately 0.5 h, a cannula (Venflon, 175 
Becton Dickinson, Helsingborg, Sweden) was inserted into an antecubital vein for further 176 
venous blood sample collection at 1, 2, 4 and 7 h post-exercise. Following each collection, the 177 
cannula was flushed with 10 mL of saline (0.9% w/v sodium chloride, Fannin Ltd, Dublin, 178 
Ireland) to maintain patency. To avoid dilution of subsequent samples, residual saline was 179 
drawn off immediately prior to each sample collection using a 2 mL syringe.  All blood samples 180 
were taken with the participant in a semi-supine position to control for any postural changes in 181 
plasma volume.  182 
Blood samples were collected into pre-chilled EDTA and lithium heparin monovettes (Sarstedt, 183 
Leicester, UK). All monovettes were centrifuged at 1750 g for 10 min at 4˚C (Heraeus 184 
Labofuge 400R, Thermo Electron, Osterode, Germany) and the resultant plasma supernatant 185 
was aliquoted into cryovials. All samples were stored at -80˚C until subsequent (batch) analysis. 186 
Haemoglobin and haematocrit concentrations were determined from each sample using 20 μL 187 
micropipettes and 20 μL heparinised microhaematocrit tubes. These measures were taken in 188 
duplicate and triplicate, respectively; and were used for subsequent estimation of changes in 189 
plasma volume (Dill and Costill 1974).  190 
Biochemical analyses 191 
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Commercially available enzyme-linked immunosorbent assays were used to determine plasma 192 
concentrations of FGF21(DF2100, R&D Systems, Oxford, UK), follistatin (DFN00, R&D 193 
Systems, Oxford UK), LECT2 (5327, MBL International, Massachusetts, USA), insulin (10-194 
113-01, Mercodia AB, Uppsala, Sweden) and glucagon (10-1271-01, Mercodia AB, Uppsala, 195 
Sweden). Samples from each participant were analysed on the same assay plate to eliminate 196 
inter-assay variation. The mean within-batch coefficients of variation (CVs) for these assays 197 
was ≤ 6.0%. Plasma glucose (A11A01668, Horiba Medical, Montpellier, France) and non-198 
esterified fatty acids (NEFA; FA115, Randox Laboratories Ltd., County Antrim, UK) were 199 
determined using enzymatic, colorimetric methods using a bench-top analyser (Pentra 400; 200 
Horiba Medical, Montpellier, France). The mean within-batch CVs for plasma glucose and 201 
NEFA were 0.43% and 1.95%, respectively. 202 
Sample size calculation 203 
Based on published data by our research group examining the effects of moderate-intensity 204 
exercise on the total area under the curve (AUC) for FGF21 in normal-weight healthy men 205 
(mean difference ± SD: 286 ± 340 pg∙mL-1∙7 h-1, giving a standardised difference of 0.84, and 206 
with an intra-person correlation of 0.76) (Sargeant et al. 2018), we required nine participants 207 
to complete our three-trial cross-over study to detect a main effect of trial for FGF21 total AUC, 208 
with 90% power and an alpha error rate of 0.05. To account for participant drop-out or non-209 
compliance, 10 individuals were recruited. Notably, based on similar data from our previous 210 
study for follistatin total AUC (mean difference ± SD: 630 ± 942 pg∙mL-1∙7 h-1, giving a 211 
standardised difference of 0.67, and with an intra-person correlation of 0.88), we also had over 212 
90% power to detect a main effect of trial on follistatin total AUC in the current study.  213 
Statistical analyses 214 
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All statistical analyses were performed using SPSS version 23 (SPSS Inc., Chicago, Illinois). 215 
The preprandial (baseline-2 h), postprandial (2-7 h) and total AUC were calculated using the 216 
trapezoidal method for all outcomes during each trial. Shapiro-Wilk tests were used to assess 217 
the distribution of the data and, when not normally distributed, data were log transformed and 218 
reassessed. Differences between exercise characteristics were assessed using paired t-tests. 219 
One-way repeated-measures analysis of variance (ANOVA) was used to examine differences 220 
between trials in baseline concentrations and AUC values for each analyte. Two-way, repeated-221 
measures ANOVA (within-participant factors: trial and time) was used to assess differences in 222 
hepatokine and metabolite responses over the duration of the different trials. Where a 223 
significant trial and interaction effect was observed, post-hoc analyses were performed using 224 
one-way ANOVAs and subsequent pairwise comparisons at each time point to locate any 225 
differences. A Bonferroni adjustment for multiple comparisons was then applied. If Mauchly’s 226 
test of sphericity was violated, Greenhouse-Geisser corrected values were used. Correction of 227 
FGF21, follistatin, glucose, NEFA, insulin and glucagon data for plasma volume changes did 228 
not alter the statistical significance of findings, therefore unadjusted values are presented. The 229 
statistical outcomes for LECT2 were altered by plasma volume adjustment, therefore statistical 230 
outcomes are presented for both adjusted and unadjusted data. An alpha value of P < 0.05 was 231 
set to indicate statistical significance. Data are presented as means ± SD or SEM, where 232 
indicated.  233 
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Results 234 
Exercise characteristics 235 
The characteristics for the MOD and HIGH exercise protocols are presented in Table 2. 236 
Treadmill speed, oxygen uptake, and relative exercise intensity were greater during HIGH 237 
compared to MOD (all P ≤ 0.001). However, the exercise duration was shorter during HIGH 238 
than MOD (P < 0.001); resulting in similar gross energy expenditures between the two exercise 239 
protocols (P = 0.459). Respiratory exchange ratio (RER) and percentage carbohydrate 240 
oxidation were significantly higher, and percentage fat oxidation significantly lower, in HIGH 241 
compared with MOD (all P ≤ 0.001). Heart rate and RPE were also greater in HIGH in 242 
comparison to MOD (both P ≤ 0.001). 243 
 244 
Insert table 2 245 
 246 
Hepatokine responses to exercise 247 
Baseline plasma concentrations of FGF21 were similar between trials (P = 0.235). Two-way 248 
ANOVA showed a significant main effect of trial and trial by time interaction for plasma 249 
FGF21 concentrations (both P < 0.001; Figure 2A). Post-hoc analyses revealed significantly 250 
higher plasma FGF21 concentrations during MOD compared to CON at 0, 1 and 2 h; and during 251 
HIGH compared to CON at 1, 2 and 4 h (all P ≤ 0.017). Additionally, plasma FGF21 252 
concentrations were significantly higher during HIGH vs MOD at 1, 2 and 4 h (all P ≤ 0.025). 253 
Table 3 details the preprandial (baseline-2 h), postprandial (2-7 h) and total FGF21 AUC. 254 
13 
 
 
Compared with control, the FGF21 AUC was higher preprandially in MOD and HIGH (P ≤ 255 
0.009) yet remained elevated postprandially only in HIGH (P = 0.001).    256 
Boxplot analysis of total trial AUC values for plasma follistatin identified one participant as an 257 
outlier (Field 2009). This was due to the participant exhibiting mean plasma follistatin 258 
concentrations during HIGH which were 13 times greater than the remaining group SD on the 259 
same trial. Consequently, all data for this participant were removed from follistatin analyses 260 
and thus results are presented for n = 9. No differences were observed in fasting plasma 261 
follistatin concentrations between trials at baseline (P = 0.138). Two-way ANOVA showed a 262 
significant main effect of trial, time and trial by time interaction for plasma follistatin 263 
concentrations (all P ≤ 0.002; Figure 2B). Post-hoc analyses revealed that when compared to 264 
CON, plasma follistatin concentrations tended to be higher at 4 h (P = 0.053) and were 265 
significantly higher at 7 h during MOD (P = 0.007).  Furthermore, plasma follistatin 266 
concentrations were significantly higher at 4 and 7 h during HIGH compared to CON (both P 267 
≤ 0.003). Examination of AUC data showed that circulating follistatin concentrations were 268 
greater in HIGH vs CON postprandially (P = 0.003; Table 3). 269 
Baseline plasma concentrations of LECT2 did not differ between trials (P = 0.108). Two-way 270 
ANOVA showed a significant main effect of time and trial by time interaction for plasma 271 
LECT2 concentrations (both P ≤ 0.004; Figure 2C). Post-hoc analyses identified elevated 272 
plasma LECT2 concentrations immediately post-exercise during MOD and HIGH trials 273 
compared to CON (both P ≤ 0.046), with a similar response between exercise trials; however, 274 
following adjustment for plasma volume changes across the trials, statistical significance did 275 
not remain (both P ≥ 0.243). No differences in AUC values were observed between trials (Table 276 
3).  277 
 278 
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Insert figure 2 279 
 280 
Insert table 3 281 
 282 
Hormone and metabolite responses to exercise 283 
Plasma hormone and metabolite responses at baseline and after exercise are shown in Figure 3. 284 
Baseline plasma concentrations of glucose, NEFA and glucagon were not statistically different 285 
between trials (all P ≥ 0.124). However, plasma insulin was significantly higher and the 286 
glucagon to insulin ratio was significantly lower at baseline in MOD compared to CON (P ≤ 287 
0.01). In response to exercise, two-way ANOVA showed a significant main effect of time and 288 
trial by time interaction for glucose and NEFA (all P ≤ 0.001), whilst a significant main effect 289 
of trial was also observed for NEFA (P < 0.001). Post-hoc analyses revealed significantly 290 
higher plasma NEFA concentrations during MOD compared to CON at 0 and 2 h; and during 291 
HIGH compared to CON at 0, 2, 4 and 7 h (all P ≤ 0.044). Additionally, plasma NEFA 292 
concentrations were significantly higher during HIGH in comparison to MOD at 4 and 7 h 293 
(both P ≤ 0.029). No significant differences in plasma glucose were found between trials at any 294 
time point (P ≥ 0.084). 295 
There was a significant main effect of time and trial by time interaction for glucagon, insulin 296 
and glucagon to insulin ratio (all P ≤ 0.002), whilst a significant main effect of trial was also 297 
observed for glucagon (P < 0.001). Post-hoc analyses revealed that when compared to CON, 298 
plasma glucagon concentrations were significantly higher at 0, 1 and 2 h during MOD and 299 
HIGH (all P ≤ 0.045). Furthermore, plasma glucagon concentrations were significantly higher 300 
at 1 h (P = 0.032) and tended to be higher at 2 h (P = 0.061) during HIGH compared to MOD. 301 
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Subsequently, a significantly greater glucagon to insulin ratio was observed at 1 h during MOD, 302 
and at 1 and 2 h during HIGH, when compared to CON (all P ≤ 0.006). However, no differences 303 
were observed between the two exercise trials (P ≥ 0.656). No significant differences in plasma 304 
insulin were found between trials at any time point post-exercise (P ≥ 0.378).  305 
 306 
Insert figure 3  307 
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Discussion 308 
The present study explored the acute effect of exercise intensity on circulating concentrations 309 
of FGF21, follistatin and LECT2 in a population of healthy men. Our novel observations are 310 
that high-intensity exercise elicited a greater post-exercise increase in circulating FGF21 when 311 
compared to moderate-intensity exercise. Furthermore, circulating follistatin was elevated after 312 
exercise independently of exercise intensity; whilst LECT2 appeared not to respond to acute 313 
bouts of exercise. 314 
FGF21 is regarded as a metabolically beneficial hepatokine which is upregulated by obesity 315 
and obesity-related diseases (Chavez et al. 2009, Dushay et al. 2010), potentially as a 316 
compensatory mechanism to preserve metabolic homeostasis (Li et al. 2018). FGF21 has also 317 
been shown to be acutely responsive to metabolic stresses such as fasting, protein restriction 318 
and exercise (Galman et al. 2008, Kim et al. 2013, Laeger et al. 2014). The findings from the 319 
present study demonstrate that the FGF21 response to acute exercise is intensity dependent, 320 
with a greater response evident after an isoenergetic bout of high- vs moderate-intensity 321 
exercise. This finding is supported by previous observations suggesting that greater post-322 
exercise increases in circulating FGF21 may be present with increasing exercise intensity (Kim 323 
et al. 2013). It must be noted, however, this previous study failed to isolate the effect of exercise 324 
intensity from the confounding influence of exercise-related energy expenditure (Kim et al. 325 
2013). Our findings also demonstrate that the exercise-induced increase in circulating FGF21 326 
persisted for up to four hours post-exercise which is consistent with previous reports from our 327 
laboratory (Sargeant et al. 2018) and elsewhere (Kondo et al. 2011).  328 
Although it is known that exercise enhances the expression and secretion of FGF21 from the 329 
liver (Kim et al. 2013, Hansen et al. 2015), the mechanisms underpinning the exercise intensity-330 
dependent increase in circulating FGF21 cannot be delineated from the present study. Our 331 
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results cannot distinguish whether the identified difference in systemic FGF21 was due to 332 
altered protein expression, secretion or clearance. Our data may, however, indicate an 333 
influential role of glucagon. Specifically, whilst no intensity-dependent differences were 334 
apparent in circulating NEFA, insulin or the glucagon to insulin ratio (all of which have been 335 
shown to modulate hepatic FGF21 secretion; Inagaki et al. 2007, Arafat et al. 2013, Hansen et 336 
al. 2015, Hansen et al. 2016b), circulating glucagon was two-fold higher in response to high- 337 
vs moderate-intensity exercise. It is therefore possible that the greater FGF21 response to high-338 
intensity exercise was mediated by a relatively larger glucagon response. This possibility is 339 
supported by preclinical data which has demonstrated an independent role of glucagon as a 340 
stimulus of hepatic FGF21 expression and secretion (Arafat et al. 2013, Habegger et al. 2013, 341 
Cyphert et al. 2014, Alonge et al. 2017, Kim et al. 2018); however, the descriptive nature of 342 
the present study prevents us from unpicking this further.  343 
It has been suggested that exercise-related augmentation of FGF21 may contribute to the 344 
beneficial metabolic effects of exercise (Hansen et al. 2016b, Weigert et al. 2018). Notably, in 345 
Wistar rats, Loyd et al (2016) recently demonstrated that FGF21 is essential for the beneficial 346 
effects of exercise training on hepatic steatosis and glycaemic control to be realised during a 347 
period of high-fat feeding. In the present study, the physiological relevance of the greater, yet 348 
transient augmentation of circulating FGF21 in response to high- vs moderate-intensity 349 
exercise, is not clear. It is possible that the enhanced response may contribute to the greater 350 
metabolic benefits associated with high-intensity exercise, including greater improvements in 351 
insulin sensitivity and glycaemic control (Hayashi et al. 2005, Rynders et al. 2014); or it may 352 
reflect a participatory role of the protein in the metabolic response to exercise and recovery. 353 
Carefully designed experiments utilising animal models are required to shed more light on this 354 
question. 355 
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Previous research has identified follistatin as another hepatokine which is transiently increased 356 
in the circulation in response to a single bout of exercise (Hansen et al. 2011, Hansen et al. 357 
2016a, Hansen et al. 2016b, Sargeant et al. 2018). In the present study, both exercise intensities 358 
led to a similar increase in circulating follistatin concentrations. Previous studies have shown 359 
that the circulating glucagon to insulin ratio is a potent stimulus of hepatic follistatin release in 360 
response to exercise (Hansen et al. 2016a, Hansen et al. 2016b). The comparable follistatin 361 
response between exercise intensities may therefore be due to equivalent changes in the 362 
circulating glucagon to insulin ratio. The importance of these gluco-regulatory hormones may 363 
help explain recent findings showing that circulating follistatin was elevated after both high-364 
intensity interval exercise and resistance exercise; but not low-to-moderate intensity 365 
continuous exercise (Perakakis et al. 2018). Although not measured in this previous study, it is 366 
likely that only the high-intensity exercise modalities would have triggered an increase in 367 
circulating glucagon and/or a decrease in circulating insulin; as opposed to the low-to-moderate 368 
intensity exercise (Wolfe et al. 1986, Lira et al. 2012).  369 
Whilst the physiological relevance of the follistatin response to exercise is not fully understood, 370 
follistatin has been identified to play a beneficial role in several metabolic actions which may 371 
be relevant to exercise. This includes promoting skeletal muscle growth and preventing 372 
degradation through its actions as a natural antagonist of myostatin (Amthor et al. 2004, Yaden 373 
et al. 2014). Moreover, chronic overexpression of follistatin promotes pancreatic β-cell 374 
survival (Zhao et al. 2015, Hansen et al. 2016a), whilst acute administration of follistatin may 375 
reduce glucagon secretion from human islets in a potential negative feedback loop (Hansen et 376 
al. 2016a). Therefore, an exercise-induced increase in circulating follistatin may contribute in 377 
some capacity to the positive metabolic effects of exercise; however, the exact role needs to be 378 
delineated further.  379 
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When interpreting the follistatin results in the present study, one important methodological 380 
consideration warranting recognition was the decision to feed participants after exercise. In 381 
previous studies, follistatin responses to exercise have been examined with study participants 382 
remaining fasted throughout experimental trials (Hansen et al. 2011; Hansen et al. 2016b). 383 
Notably, the magnitude of increase in circulating follistatin after exercise in these previous 384 
studies was considerably greater than observed in the present study. It is therefore possible that 385 
food consumption may have blunted the follistatin response after exercise in the present study. 386 
In particular, evidence suggests that insulin may inhibit follistatin production (Tao et al. 2018); 387 
including the response to exercise (Hansen et al. 2016b). Raised postprandial insulin may have 388 
blunted our ability to detect an effect of exercise intensity on circulating follistatin within our 389 
post-exercise observation period. An additional experiment is needed to test this hypothesis. 390 
LECT2 is a novel hepatokine whose circulating levels are elevated in obesity, type 2 diabetes 391 
and non-alcoholic fatty liver disease (Okumura et al. 2013, Zhang et al. 2018). In vitro studies 392 
have shown that LECT2 triggers inflammation in vascular endothelium (Hwang et al. 2015) 393 
and directly inhibits insulin signalling in C2C12 myocytes (Lan et al. 2014) and 3T3-L1 394 
adipocytes (Jung et al. 2018). It has therefore been suggested that LECT2 may provide a 395 
mechanistic link between NAFLD, T2DM and cardiovascular disease (Meex and Watt 2017).  396 
In our previous research, 60 min of moderate-intensity treadmill exercise had no impact on 397 
circulating LECT2 concentrations for up to 6 h post-exercise in healthy lean and overweight 398 
men (Sargeant et al. 2018). Based on previous rodent data showing a negative regulatory 399 
influence of hepatic AMPK-phosphorylation on LECT2 expression (Lan et al. 2014), we 400 
hypothesised in the present study that high-intensity exercise would suppress circulating 401 
LECT2. In contrast, we observed a significant increase in circulating LECT2 concentrations 402 
immediately after both moderate- and high-intensity exercise; with no differences apparent in 403 
20 
 
 
the hours thereafter. It must be noted, however, that statistical significance was lost at the 0 h 404 
time point following adjustment for plasma volume changes, despite similar effect sizes (ES) 405 
remaining (Cohen’s d before vs after plasma volume adjustment: ES = 0.41 vs ES = 0.49 and 406 
ES = 0.42 vs ES = 0.45 for MOD and HIGH compared to CON, respectively). Therefore, 407 
exercise-induced haemoconcentration may have contributed, in part, to the observed increase 408 
in plasma LECT2 immediately after exercise.    409 
Lan et al (2014) previously showed that hepatic LECT2 expression and circulating 410 
concentrations were suppressed immediately after 3 h of treadmill running in C57BL/6J mice. 411 
This contrasting finding with our work may be related to species differences but may also be 412 
due to the nature of the exercise utilised and/or the study participants. Specifically, given the 413 
negative regulatory influence of hepatic AMPK, longer duration exercise with a greater 414 
metabolic challenge may be needed to suppress LECT2 in humans. It is also possible that this 415 
response may only occur in individuals with obesity in which circulating LECT2 is elevated; 416 
however additional studies in populations with obesity are needed to test these hypotheses. 417 
A key strength of our study is the precision with which exercise-related energy expenditure 418 
was matched. Conversely, a limitation of the present study is that the observed hepatokine 419 
responses occurred in a population of young, healthy men. Circulating levels of hepatokines 420 
are modulated by adiposity and associated metabolic disease and, therefore, we cannot be 421 
certain that our findings translate to different populations. The therapeutic benefits of exercise 422 
are greater in clinical populations and therefore additional studies should investigate the 423 
influence of exercise of varied intensities and durations in individuals with obesity and 424 
associated metabolic disease.  425 
In conclusion, this study demonstrates that circulating concentrations of FGF21 and follistatin 426 
are transiently increased in response to acute bouts of aerobic exercise, whereas circulating 427 
21 
 
 
LECT2 concentrations may not be sensitive to acute exercise stimuli. Furthermore, exercise 428 
increases circulating FGF21 in an intensity-dependent manner, whilst the exercise-induced 429 
increase in circulating follistatin may be independent of exercise intensity.  These findings 430 
support the notion that FGF21 and follistatin may contribute to the favourable metabolic effects 431 
of exercise and a dose-dependent increase in FGF21 secretion may be partly responsible for 432 
the additional benefits of high-intensity exercise. Additionally, these data extend our 433 
understanding of the acute regulation of hepatokines in humans and may help to inform future 434 
therapeutic interventions targeted at manipulating hepatokine concentrations.  435 
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Tables 616 
Table 1. Participant characteristics (n = 10). 617 
Characteristic Mean ± SD 
Age (years) 26 ± 2 
Height (m) 1.77 ± 0.07 
Body mass (kg) 80.2 ± 6.2 
BMI (kg∙m-2) 25.6 ± 1.7 
Waist circumference (cm) 83.7 ± 4.1 
Body fat (%) 15.4 ± 4.4 
V̇O2 peak (mL∙kg-1∙min-1) 49.8 ± 5.3 
      Note: BMI, body mass index; V̇O2 peak, peak oxygen uptake.  618 
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Table 2. Exercise characteristics (n = 10). 619 
 MOD HIGH P-value 
Treadmill speed (km∙h-1) 8.2 ± 1.4 11.6 ± 1.6 <0.001 
Oxygen uptake (L∙min-1) 2.17 ± 0.26 2.98 ± 0.37 <0.001 
Exercise intensity (%V̇O2 peak) 54.6 ± 1.7 74.7 ± 1.8 <0.001 
Exercise duration (min) 57 ± 8 42 ± 6 <0.001 
Gross energy expenditure (kJ) 2475 ± 70 2488 ± 58 0.459 
Respiratory exchange ratio 0.90 ± 0.03 0.99 ± 0.03 !<0.001 
Carbohydrate oxidation (%) 67 ± 10 94 ± 8 <0.001 
Fat oxidation (%) 33 ± 10 6 ± 8 <0.001 
Heart rate (beats∙min-1) 142 ± 10 168 ± 9 <0.001 
Rating of perceived exertion  11 ± 2 16 ± 1 <0.001 
    Note: Data are presented as means ± SD. V̇O2 peak, peak oxygen uptake.  620 
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Table 3. Area under the hepatokine concentration vs time curve during CON, MOD and 621 
HIGH trials for the preprandial (BL-2 h), postprandial (2-7 h) and total trial (8 h) periods. 622 
 CON MOD HIGH 
FGF21 (n = 10)  
Preprandial AUC  
(pg∙mL-1 BL-2 h) 
144 ± 124 230 ± 156a 334 ± 249a§ 
Postprandial AUC  
(pg∙mL-1 2-7 h) 
264 ± 209 323 ± 233 433 ± 271a 
Total AUC (pg∙mL-1 8 h) 407 ± 330 553 ± 377a 768 ± 491a§ 
Follistatin (n = 9)  
Preprandial AUC  
(pg∙mL-1 BL-2 h) 
3848 ± 515 4518 ± 1148 4566 ± 962# 
Postprandial AUC  
(pg∙mL-1 2-7 h) 
6615 ± 823 8504 ± 2118# 9275 ± 1406a 
Total AUC (pg∙mL-1 8 h) 10463 ± 1162 13022 ± 3175# 13841 ± 2110a 
LECT2 (n = 10)          
Preprandial AUC  
(ng∙mL-1 BL-2 h) 
157 ± 59 165 ± 64 166 ± 62# 
Postprandial AUC  
(ng∙mL-1 2-7 h) 
253 ± 98 267 ± 102 268 ± 99 
Total AUC (ng∙mL-1 8 h) 410 ± 156 432 ± 166 434 ± 160 
    Note: Data are presented as means ± SD. FGF21, fibroblast growth factor 21; AUC, area 623 
under curve; BL, baseline; LECT2, leukocyte cell-derived chemotaxin 2.  624 
     aSignificantly different from CON (P < 0.05). 625 
    #Tended to differ from CON (P < 0.07). 626 
    §Tended to differ from MOD (P < 0.07). 627 
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Figure captions 628 
Figure 1. Schematic illustration of the main trial protocol. Duration of exercise in MOD and 629 
HIGH = 57 ± 8 and 42 ± 6 min, respectively. Participants were provided with 35% of 630 
estimated daily energy requirements at both 2 h and 6 h. 631 
 632 
Figure 2. Plasma concentrations of fibroblast growth factor 21 (FGF21) (A), follistatin (B) 633 
and leukocyte cell-derived chemotaxin 2 (LECT2) (C) during the control (open circles), 634 
moderate-intensity exercise (black circles) and high-intensity exercise (grey circles) trials. 635 
Data are presented as means ± SEM, n = 10 for FGF21 and LECT2 data, and n = 9 for 636 
follistatin data. Black rectangle indicates moderate-intensity exercise, grey rectangle indicates 637 
high-intensity exercise and hatched rectangles indicate test meals. BL, baseline. aMOD 638 
significantly different from CON (P < 0.05); bHIGH significantly different from CON (P < 639 
0.05); cHIGH significantly different from MOD (P < 0.05). 640 
 641 
Figure 3. Plasma concentrations of glucose (A), non-esterified fatty acids (NEFA) (B), 642 
glucagon (C), insulin (D) and the glucagon to insulin ratio (E) during the control (open 643 
circles), moderate-intensity exercise (black circles) and high-intensity exercise (grey circles) 644 
trials. Data are presented as means ± SEM. Black rectangle indicates moderate-intensity 645 
exercise, grey rectangle indicates high-intensity exercise and hatched rectangles indicate test 646 
meals. BL, baseline. aMOD significantly different from CON (P < 0.05); bHIGH significantly 647 
different from CON (P < 0.05); cHIGH significantly different from MOD (P < 0.05). 648 
 649 
 650 
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